Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2020
SIETES contiene 93129 citas

 
 
<< anterior 21 a 40 de 309 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Goette A, Merino JL, Ezekowitz MD, Zamoryakhin D, Melino M, Jin J, Mercuri MF, Grosso MA, Fernandez V, Al-Saady N, Pelekh N, Merkely B, Zenin S, Kushnir M, Spinar J, Batushkin V, de Groot JR, Lip GYH, ENSURE-AF investigators. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. [Ref.ID 100910]
22. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
23. Cita con resumen
Hirschler B. AstraZeneca pauses two cancer drug trials' enrolment due to bleeding. Reuters Health News 2016:1. [Ref.ID 100864]
27. Cita con resumen
Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-33. [Ref.ID 100788]
29. Cita con resumen
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Lafky JM, Loprinzi CL. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-42. [Ref.ID 100630]
30. Cita con resumen
Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]
31. Cita con resumen
32.Tiene citas relacionadas Cita con resumen
Anónimo. FDA staff reviewers split over brodalumab’s suicide risk. DIA Daily 2016:1. [Ref.ID 100494]
34.Enlace a cita original Cita con resumen
Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB, ICON6 Collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016;387:1066-74. [Ref.ID 100153]
35.Tiene citas relacionadas Cita con resumen
Eichler H-G, Hurts H, Broich K, Rasi G. Drug regulation and pricing — Can regulators influence affordability?. N Engl J Med 2016;374:1807-9. [Ref.ID 100113]
36. Cita con resumen
Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Martin P, Pol S, Londoño M-C, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen B-Y, Robertson M, Barr E, Wahl J, Greaves W. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 2015;386:1537-45. [Ref.ID 99620]
37.Tiene citas relacionadas Cita con resumen
Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP, for the TRAFFIC and TRANSPORT Study Groups. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 2015;373:220-31. [Ref.ID 99349]
38. Cita con resumen
Ngandu T, Lehtisalo J, Solomon AJ, Levälahti E, Ahtiluoto S, Antikainen RL, Bäckman L, Hänninen T, Jula A, Laatikainen T, Lindström J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Raumaraa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-63. [Ref.ID 99282]
39. Cita con resumen
Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD, Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015;38:565-75. [Ref.ID 99239]
40.Tiene citas relacionadas
Davis PB. Another beginning for cystic fibrosis therapy. N Engl J Med 2015;373:274-6. [Ref.ID 99113]
Seleccionar todas
 
<< anterior 21 a 40 de 309 siguiente >>